R-bambuterol - Lotus Pharmaceuticals

Drug Profile

R-bambuterol - Lotus Pharmaceuticals

Alternative Names: Laevo bambuterol

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dong Guan Kai Fa Biologicals Medicine
  • Developer Lotus Pharmaceuticals
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Asthma(In volunteers) in China (PO, Tablet)
  • 27 Oct 2010 State Food and Drug Administration approves phase I pharmacokinetic trial of R-bambuterol in healthy volunteers in China
  • 26 Aug 2010 Phase-I clinical trials in Asthma (in volunteers) in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top